By Fineline Cube 
Shenzhen-based Lancet Robotics, a developer of orthopedic joint replacement surgical robots, has reportedly secured “tens of millions” of renminbi in a Series A+ financing round. The funds will be directed toward establishing an industrial base for domestically produced cross-department surgical robots, advancing subsequent product R&D, and driving global commercialization efforts. This move aims to further solidify the company’s leadership in innovative surgical robotics in China.
Company Mission and Solutions
Lancet Robotics is committed to providing comprehensive AI-powered surgical robotics solutions for medical institutions. The company’s portfolio includes five Class III medical device registrations, such as its hip-knee integrated joint replacement surgical robot and dental implant surgical robot. It has also obtained one U.S. FDA 510(K) clearance and two Class II medical device registrations.
Intellectual Property and Innovation
To date, Lancet Robotics has filed nearly 400 intellectual property applications, including 166 invention patents, underscoring its commitment to innovation in the field of surgical robotics.-Fineline Info & Tech